CHU Clermont-Ferrand - Site Estaing ( Site 0249)

Clermont-Ferrand, Puy-de-Dome 63003

0 studies enrolling now · 1 studies all time

What they study most

Biliary Tract Carcinoma

Studies at this site

• Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) — Completed